StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) stock

RGCNasdaqMedicinal Chemicals & Botanical Products
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.18−0.18 (-4.13%)

Close on Nov 20, 2026Market cap $2.07BP/E –Yield –

Regencell Bioscience net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2026 it was -$11.70M. The highest annual figure on record is -$390.99K in fiscal 2019.

Annual net income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$11.70M–
FY2025Jun 30, 2025-$3.58M–
FY2024Jun 30, 2024-$4.30M–
FY2023Jun 30, 2023-$5.87M–
FY2022Jun 30, 2022-$7.45M–
FY2021Jun 30, 2021-$1.35M–
FY2020Jun 30, 2020-$812.37K–
FY2019Jun 30, 2019-$390.99K–

More Regencell Bioscience figures

See a number that looks wrong?